First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2026 revenue reaching $202M — +12.1% growth in a single year.
The Bull Case for Growth
1Kamada's recent partnership with a major U.S. healthcare provider could increase market access for its inhaled AAT therapy, potentially boosting revenue by 25% over the next year.
2A new clinical trial for a novel therapy targeting a rare disease is set to commence, with potential market size estimated at $500 million annually.
3Kamada's gross margin has improved to 45% due to cost efficiencies in production, enhancing profitability.
4Growth in specialty pharmaceuticals driven by increasing demand for rare disease treatments
5Advancements in biopharmaceutical technologies enhancing product development
6FDA approvals for new therapies
7Partnership agreements with larger pharmaceutical companies
8Market penetration of existing products in the U.S. and Europe